Taylor Sandison is Chief Medical Officer at Cidara Therapeutics, Inc. (CDTX). They have made 6 open-market trades across 1 company since 2017, most recently 2024-09-11.
CIK 0001702287
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $232K since 2017, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CDTX | 23,067 | $5.1M |
Shares reported on the most recent Form 4, priced at the 2024-09-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CDTX | SELL | 2024-09-11 | 2024-09-13 | $11.64 | $11K | -9.9% | -14.2% | +80.2% |
| CDTX | SELL | 2024-03-11 | 2024-03-12 | $0.67 | $14K | +15.9% | +28.8% | +0.1% |
| CDTX | SELL | 2023-09-11 | 2023-09-13 | $0.95 | $18K | -12.6% | -17.1% | -35.6% |
| CDTX | SELL | 2023-03-13 | 2023-03-13 | $1.53 | $11K | -17.3% | -37.0% | -28.9% |
| CDTX | SELL | 2022-09-12 | 2022-09-13 | $0.68 | $13K | -5.4% | -16.5% | -25.6% |
| CDTX | BUY | 2017-06-06 | 2017-06-08 | $5.90 | $232K | +13.9% | +17.2% | +9.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.